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Abstract: Helicobacter pylori (H.pylori) infection induces inflammation in gastric mucosa that may progress to 
gastric cancer that causes of much mortality. This cancer is a multistage process involved changes in environmental, 
genetic and epigenetic factors. Polymorphism in promoter of CDH1 gene is associated with reduced E-cadherin 
protein expression. Gastric cancer is associated with multiple changes nucleotides in CDH1 gene. Aimed: We were 
evaluating -160 (C>A) CDH1 gene polymorphism associations with gastric cancer in Kurdish population. Methods: 
A total of 306 biopsies taken from corpus of 144 gastric cancer patients and 162 nonulcer dyspepsia patients were 
classified as H.pylori-infected and H.pylori-uninfected. All diagnoses confirmed pathologically and molecularly. 
Polymorphism in -160(C>A) CDH1 was evaluated by PCR-RFLP. Results: Polymorphism of -160 (C>A) CDH1 in 
H.pylori-uninfected and H.pylori-infected groups were not associated with gastric cancer (p > 0.05). Also there was 
not relationship between -160(C>A) CDH1 genotypes and H.pylori infection susceptibility (p > 0.05). We found 
significant relationship between CC genotype and survival time among gastric cancer patients (p = 0.01). 
Conclusion: -160(C>A) CDH1 polymorphism may regardless of presence or absence of H.pylori, don’t influences 
gastric cancer sensibility in Kurdish population. In other hand CC genotype, as a good trait, increases period of life 
for Kurdish cancer patients. 
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Introduction
           H.pylori is a spiral-shaped gram negative 
flagellate bacterium that colonizes the gastric mucosa 
of approximately 50 % of the world's population (1-
3). H.pylori infection induces inflammation in gastric 
mucosa that involved in chronic gastritis (4-
6).Gastritis may progress to other steps Such as, 
gastric atrophy, intestinal metaplasia, and gastric 
cancer (7, 8). Gastric cancer is causes of many 
mortality in America, however, over the past few 
decades rate of gastric cancer progress has fallen 
sharply in developed countries (9). Nevertheless, 
gastric cancer is a major cause of cancer result to 
death in developing countries, as after lung cancer 
remains the second highest cause of death in the 
world (10). Environmental factors play an important 
role in the risk of gastric cancer (11). This cancer is 
still the most common cause of gastric gland 
epithelium (9, 10). It has been established that gastric 
cancer is a multistage process involved changes in 
environmental factors, genetic factors and epigenetic 
factors. Probable genetic risk factors such as single 
nucleotide polymorphisms (SNPs) in several 
pathways causing chronic inflammation of gastric 
mucosa and carcinogenesis in the next steps. The 
involved SNPs affect agents such as: pro-
inflammatory cytokines, xenobiotic metabolizing 
enzymes, and growth factors (12-18). The study of 
these molecular pathways has helped to identify 
individuals at higher risk, particularly when 
examined with H. pylori infection and other 
environmental exposure (14, 15).  Among genetic 
factors CDH1 is one of the most important tumor 
suppressor genes and is the good example of the 
potential tumor suppressor gene that is involved 
preferentially in cancer (19). Adhesion molecules, 
especially the calcium-dependent intercellular 
adhesion molecule E cadherin and its CDH1 gene 
(located on chromosome 16), play a central role in 
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carcinogenesis and metastasis (17, 20). The CDH1 
gene encodes a transmembrane glycoprotein that 
mediates intercellular adhesion and cellular polarity. 
The E-cadherin protein is a tumor invasion 
suppressor, and loss of its function results in 
transition to an invasive phenotype in human 
epithelial cancers (17, 20). Polymorphisms in genes 
that increase the risk of cancer progression, including 
CDH1 gene is considerable. So that polymorphism in 
some regions of CDH1 gene increases the risk of 
cancer progression. Also some polymorphisms in 
promoter of CDH1 gene is associated with reduced 
E-cadherin protein expression (21). In the number of 
cancers dysfunction in regulation of CDH1 gene 
expression, particularly reduced expression of CDH1 
gene, has been observed. There are many SNPs 
within or around the CDH1 gene that located in 
upstream gene and within promoter or in coding 
region. Example of these SNPs are +54 T> C, -160 
C> A, -616 G> C and -3159 T> C that associated 
with transcription initiation (21). Gastric cancer is 
associated with multiple changes nucleotides in 
CDH1 gene (21). Many studies have found that 
different races have different polymorphisms of this 
gene that result in differ susceptibility of gastric 
cancer risk. Accordingly, we have chosen -160(C>A) 
polymorphism of CDH1 gene to examine any 
possible association with gastric cancer in Kurdish 
population (21). 
 
Subjects and methods 
          144 Kurdish patients with gastric cancer who 
underwent surgery at the first affiliated Hospital and 
cancer center of Kurdistan University of medical 
sciences, Kurdistan, Iran, were consecutively 
recruited from 2004 to 2009. All diagnoses were 
pathologically confirmed. The control series included 
162 Kurdish nonulcer dyspepsia (NUD) who were 
undergoing upper gastrointestinal endoscopy. In both 
groups, cases and controls, H.pylori infection was 
determined by the UBT (Urease Breath Test) and 
PCR 16srRNA (22) on biopsies taken from the 
corpus. Patients were classified as H.pylori -infected 
only if the two tests were positive and H.pylori-
uninfected if the two tests were negative, 
respectively. Demographic and clinical data were 
obtained from subjects through interview using a 
standard clinical pro forma. Survival data were 
obtained from a follow-up of the patients after 
surgery. Exclusion criteria included history of gastric 
neoplasm or surgery, liver disease, and previous 
treatment with nonsteroidal anti-inflammatory drugs, 
proton pump inhibitors, antibiotics, or bismuth salts. 
Informed consents for participation were signed by 
all subjects. The study protocol was approved by the 
Clinical Research Ethics Committee of the Kurdistan 
University of Medical Sciences. 
 
Histological examination 
          Sections of biopsy specimens were embedded 
10 % buffered formalin and stained with hematoxylin 
and eosin to examine gastritis and with giemsa to 
detect H.pylori (23). The histological examination of 
gastric mucosa were blindly performed according to 
the Updated Sydney system (24). 
DNA isolation 
          DNA of gastric cancer patients was separated 
from paraffin embedded tumor tissues using QIAamp 
DNA Mini Kit (Qiagen, Germany). DNA of controls 
was extracted from biopsies taken from the corpus 
using Biospin Tissue genomic DNA Extraction Kit 
(Bio Flux, Japan). All extracted DNA was 
resuspended in UltraPure RNAse/DNAse-Free 
Distilled water. 
Genotyping for -160 (C>A) CDH1 polymorphism 
          Genotyping analysis of -160 (C>A) CDH1 
were performed by polymerase chain reaction 
restriction fragment length polymorphism (PCR-
RFLP). Primer sequences for -160(C>A) variation of 
CDH1 gene are as follows: sense 5´-TGATCCCAG 
GTCTTAGTGAG-3´, anti-sense 5´-
AGTCTGAACTGACTTCCGCA-3´. The PCR 
amplification was performed in a total volume of 25 
µL mixture containing: 100 ng genomic DNA, 1.0 
mM of each primer, 200 mM of each dNTP, 2.0 mM 
of MgCl2 and 1.0 U Taq DNA polymerase and 10 X 
Taq buffer (Fermentas) using the Biometra Tgradient 
96 (Biometra, Germany). PCR conditions were as 
follows: denaturation at 95 oC for 5 min, followed by 
35 cycles of 95 oC for 30 s, 58 oC for 30 s, and 72 oC 
for 30 s. A final extension was carried out at 72 oC 
for 5 min and cooling down to 4 oC. The PCR 
products were digested by restriction endonuclease 
BesEII (Fermentas), according to the manufacturer’s 
instructions, at 37°C overnight and then separated by 
3% agarose gel electrophoresis. Gel analysis was 
performed after staining with ethidium bromide. PCR 
products were shown to be digested into three types 
of fragments (Fig. 1). To confirm the genotyping 
results, selected PCR samples in both groups 
including samples of each genotype were re-
genotyped by other laboratory personnel. There was 
no difference after sequencing the randomly selected 
samples. 
Statistical analysis 
          Data were analyzed using SPSS 16.0 (SPSS 
Inc., Chicago, IL). Hardy–Weinberg equilibrium in 
all subjects was analyzed with the x2 goodness-of-fit 
test before the ensuing analyses. The confounding 
effects of age and gender were adjusted using 
conditional logistic regression. Also Statistical 
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analysis was performed by non-paired t-test 
depending on the data set. Values of p <0.05 were 
considered as significant. Kaplan–Meier survival 
curves and the log-rank test for trend were used to 
evaluate the relationship between genotypes and the 
outcome of patients to the end of follow-up. 
 
 
Fig 1:PCR-RFLP 3% agarose gel electrophoresis of 
the -160(C>A) CDH1 polymorphism indicating 
No.12 (AA = 328 bp) 1, 3, 4, 5, 7, 8, 9, 10, 13, 15, 18 
(AC = 328, 218, 110 bp) 2, 6, 11, 14, 16, 17, 19, 20 
(CC = 218, 110 bp) genotypes. 
 
Results 
Demographic and clinical characteristics 
          Genomic DNA was obtained among the 144 
(44.4%) gastric cancer and 162 (55.6%) non-gastric 
cancer subjects then the DNA all subjects were 
genotyped. The demographic data of all subjects 
were demonstrated in Table 1. There was no 
significant difference between the two groups with 
respect to the age and gender distribution (p > 0.05). 
 
Table 1: Demographic data of study subjects. 
Variable Case (%) Control (%) 
 
Overall   
 
144 (44.4%) 
 
162 (55.6%) 
Gender 
Male 
Female 
 
81 (56.2%) 
63 (43.8%) 
 
  87 (53.7%)    
75 (46.3%)   
Age  Mean±SD 
(year)   
 
59.52 ±15 
 
59.4 ±15.5 
 
. 
-160(C>A) CDH1 polymorphism and susceptibility 
to gastric cancer 
          The frequencies of the polymorphism in cases 
and controls are shown in Table 2. Frequencies of -
160(C>A) CDH1 genotypes in gastric cancer patients 
(CC, 52.8%; CA, 46.5% and AA, 0.7%) were 
compared with those in control subjects (CC, 58.8%; 
CA, 41.2% and AA, 0.0%). There was no significant 
relationship between -160(C>A) CDH1genotypes 
and susceptibility to gastric cancer. 
 
Table 2: Adjusted 95% confidence intervals (CIs) for 
-160(C>A) CDH1 polymorphism in relation to 
gastric cancer 
# p < 0.05 was considered statistically significant. 
 
Evaluation of -160(C>A) polymorphism and 
susceptibility to H.pylori infection  
          In our population study -160(C>A) CDH1 
genotypes evaluated in H.pylori-infected and 
H.pylori -uninfected population (Table 3). Genotypes 
of -160(C>A) CDH1 Compared in H.pylori -infected 
and H.pylori-uninfected subjects in case group (p = 
0.778) and control group (p = 0.44). There was no 
significant relationship between -160(C>A) CDH1 
genotypes and susceptibility to H.pylori infection.  
 
Table 3: Adjusted 95% confidence intervals (CIs) for 
-160(C>A) CDH1 polymorphism and susceptibility 
to H.pylori infection 
# p < 0.05 was considered statistically significant. 
 
Evaluation of -160(C>A) CDH1 polymorphism 
and survival of gastric cancer patients  
          Overall survival of the gastric cancer patients 
was analyzed using Kaplan–Meier survival curves for 
dependence on -160(C>A) CDH1 genotypes. There 
was significant difference among AC and CC 
genotypes in gastric cancer patients. According to the 
survival months gastric cancer patients with genotype 
of CC, live longer than gastric cancer patients with 
AC genotype after cancer (Table 4). 
 
 
Genotype Case (%) Control (%) 
-160(C>A) CDH1   
AA 1 (0.7%) 0 (0.0%) 
AC 67 (46.5%) 57 (41.2%) 
CC 76 (52.8%) 105 (58.8%) 
#P value  0.281   
Genotypes 
of CDH1   
H.pylori-
infected (%) 
H.pylori-
uninfected (%) 
#P value  
case 
AA 
AC 
CC 
 
0 (0.0%) 
46 (31.9%) 
55 (38.2%) 
 
1 (0.7%) 
21 (14.6%) 
21 (14.6%) 
 
 
 
0.778 
control 
AA 
AC 
CC 
 
  0 (0.0%) 
48 (44.4%) 
60 (55.6%) 
 
0 (0.0%) 
9 (16.7%) 
45 (83.3%) 
 
 
 
0.44 
 Life Science Journal 2013;10(12s)          http://www.lifesciencesite.com 
 
215 
Table 4. Cox multivariate regression analysis of 
potential factors for overall survival in gastric cancer 
patients 
-160(C>A) CDH1 
Genotypes   
Frequency Survival 
(Months) 
*AA * * 
AC 51 18 
CC 66 24.82 
#P value  0.01 
*The sample size of AA was small so it was not 
statistically significant. # p < 0.05 was considered 
statistically significant. 
 
Discussion 
          CDH1 gene located on chromosome 16 (1/22 q 
16). The role of this gene is expression cellular 
adhesion proteins on epithelial cells. E-cadherin 
protein that resulting from expression of CDH1 gene, 
acts as a tumor suppressor (25). Mutations and 
impaired function of this gene has been found in 
gastric cancer (26). There is no data regarding CDH1 
gene polymorphism on gastric cancer among Kurdish 
population till date. Since the CDH1 gene may play a 
major role in the development of gastric cancer, we 
studied polymorphism in the region promoter, -160 
(C > A), of CDH1 gene to evaluate whether this 
polymorphism can affect the CDH1 gene in this 
population with gastric cancer. In the present study 
we found that frequencies of -160(C>A) CDH1 
genotypes were not comparable in H.pylori-infected 
and H.pylori -uninfected subjects in both of case and 
control groups. These findings suggest that -160 
(C>A) CDH1 polymorphism don’t relate with 
H.pylori infection susceptibility. Also, we found that 
variants of -160(C>A) CDH1 were not associated 
with gastric cancer susceptibility in case and control 
groups. In other hand we observed gastric cancer 
patients with CC genotype have a longer survival 
than gastric cancer patients with AC genotype 
significantly. This result proposed CC as a good 
genotype in the process of cancer but not in gastric 
cancer susceptibility, in Kurdish population. 
          Molecular epidemiological studies evaluated 
the relationship between polymorphism of -160 
(C>A) CDH1gene and cancer. As a result, different 
cancers including: prostate, breast, colorectal and 
gastric cancer have different outcomes in different 
regions of the world. In a case-control study in the 
United Kingdom 433 patients with gastric cancer and 
466 healthy controls were studied and finally 
declared that the genotype frequencies did not differ 
significantly between controls and patients , as a 
result, polymorphism of -160(C>A) CDH1 gene 
promoter was not associated with gastric cancer (27). 
In 2005, lu .y et.al studied 206 gastric cancer patients 
and 261 healthy controls in China and finally 
announced that -160 (C>A) CDH1 gene 
polymorphism may not have a major role in the 
development of gastric cancer in Chinese (28). In 
2008, the French jenab, et. al were investigated 245 
gastric cancer patients and 950 control subjects. They 
determined there is no association between 
polymorphisms -160(C>A) in the CDH1 gene and 
gastric cancer (29). Chen B, et.al conducted a meta-
analysis in China suggested that CDH1 gene 
polymorphic region of -160(C>A) don’t have the role 
at increasing risk for gastric cancer (30). These 
results are consistent with our study but are 
inconsistent with the below studies.  
          In a study Yadong Wang, et.al in 2011 
evaluated the polymorphism -160(C>A) CDH1 gene 
and the risk of colorectal cancer. In a result, this 
polymorphism was associated with increased risk for 
colorectal cancer (31). Another study in 2010 in 
Oman by AL. Moundir MS, et.al reported that the 
polymorphism in -160(C>A) CDH1 gene promoter is 
associated with increased risk for gastric cancer (32). 
Finally, we must acknowledge that the CDH1 gene 
polymorphism at position -160(C>A) has a various 
outcomes in different ethnic groups and geographic 
locations. This polymorphism should be evaluated 
with other environmental factors simultaneously. 
Therefore, further studies are needed to confirm our 
findings. 
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